Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Innate immunity constitutes the body’s first line of defence against invading pathogens. This ancient, evolutionarily conserved system is activated within minutes of encountering foreign agents, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results